Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than a buck. -- Ignore unavailable to you. Want to Upgrade?

To: RWReeves who wrote (543)	5/7/2000 11:57:00 PM
From: chirodoc	Read Replies (1) \| Respond to of 743

kendl and blud look interesting. i like the earnings and the low p/e--looks safe in a tough market. i don't like the meager profit margins. since we are talking UNDER 10, i will give you my long term play--AVAN. very full pipeline--a product in late stage trials, a number of potential big drugs and one blockbuster (CETP)in the pipeline. curtis

To: RWReeves who wrote (543)	7/10/2000 5:16:13 PM
From: nigel bates	Read Replies (1) \| Respond to of 743

(Still holding my VVUS too...) biz.yahoo.com LEXINGTON, Mass., July 10 /PRNewswire/ -- MacroChem Corporation (Nasdaq: MCHM - news) announced today it will begin a pivotal Phase 3 clinical trial of its investigational topical impotence drug, Topiglan(TM), following favorable U.S. Food & Drug Administration review of its proposed trial protocol. This pivotal Phase 3 trial is the first pivotal trial of a topical ED therapy to be initiated in the U.S.* (Photo: newscom.com Don't bother, the photo isn't what you might expect (g). nig